Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Avanos Medical Inc

Healthcare US AVNS

24.93USD
0.03(0.12%)

Last update at 2026-06-23T20:01:00Z

Day Range

24.8924.94
LowHigh

52 Week Range

9.3024.72
LowHigh

Fundamentals

  • Previous Close 24.90
  • Market Cap1150.05M
  • Volume352675
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA54.40M
  • Revenue TTM701.20M
  • Revenue Per Share TTM15.14
  • Gross Profit TTM 353.90M
  • Diluted EPS TTM-1.57

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -66.20000M -403.30000M -7.90000M 65.20M 5.80M
Minority interest - - - - -
Net income -67.90000M -392.10000M -61.80000M 50.50M 5.20M
Selling general administrative 315.60M 318.50M 335.00M 341.90M 300.30M
Selling and marketing expenses - - - - -
Gross profit 349.00M 381.30M 379.70M 450.00M 364.30M
Reconciled depreciation 38.90M 45.50M 46.10M 47.70M 38.30M
Ebit -62.20000M -391.10000M 7.10M 74.00M 8.90M
Ebitda -33.20000M -345.60000M 50.60M 122.90M 47.40M
Depreciation and amortization 29.00M 45.50M 43.50M 48.90M 38.50M
Non operating income net other - - - 1.20M 0.20M
Operating income -61.60000M 40.00M 65.00M 74.00M 8.90M
Other operating expenses 762.80M 647.80M 608.30M 746.00M 735.70M
Interest expense 4.00M 12.20M 15.00M 10.00M 3.30M
Tax provision 6.70M -17.00000M 2.00M 14.70M 0.60M
Interest income 3.20M 5.10M 2.90M 1.20M 0.20M
Net interest income -4.60000M -7.10000M -12.10000M -8.80000M -3.10000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.70M -17.00000M 2.00M 14.70M 0.60M
Total revenue 701.20M 687.80M 673.30M 820.00M 744.60M
Total operating expenses 410.60M 341.30M 314.70M 376.00M 355.40M
Cost of revenue 352.20M 306.50M 293.60M 370.00M 380.30M
Total other income expense net -4.60000M -443.30000M -72.90000M -8.80000M -3.10000M
Discontinued operations - - - - -
Net income from continuing ops -72.90000M -386.30000M -9.90000M 50.50M 5.20M
Net income applicable to common shares - - - 50.50M 5.20M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1073.70M 1154.20M 1692.40M 1786.90M 1594.60M
Intangible assets 117.80M 112.30M 239.50M 251.00M 141.20M
Earning assets - - - - -
Other current assets 13.80M 14.10M 93.30M 13.90M 18.60M
Total liab 295.50M 325.70M 456.10M 495.70M 330.70M
Total stockholder equity 778.20M 828.50M 1236.30M 1291.20M 1263.90M
Deferred long term liab - - - 25.40M 9.60M
Other current liab 91.30M 73.30M 127.40M 98.90M 68.10M
Common stock 0.50M 0.50M 0.50M 0.50M 0.50M
Capital stock 0.50M 0.50M 0.50M 0.50M 0.50M
Retained earnings -779.90000M -707.00000M -314.90000M -253.10000M -310.30000M
Other liab - - - 48.90M 18.70M
Good will 394.90M 455.60M 796.10M 819.40M 801.60M
Other assets - - - 22.20M 26.50M
Cash 89.80M 107.70M 87.70M 127.70M 118.50M
Cash and equivalents - - - - -
Total current liabilities 165.20M 165.90M 234.60M 185.80M 139.20M
Current deferred revenue - - - - -
Net debt 39.30M 62.50M 121.40M 152.30M 69.00M
Short term debt 18.40M 20.30M 34.20M 19.00M 14.70M
Short long term debt 10.20M 9.40M 8.60M 6.20M -
Short long term debt total 129.10M 170.20M 209.10M 280.00M 187.50M
Other stockholder equity 1589.60M 1579.60M 1577.70M 1579.60M 1607.50M
Property plant equipment - - - 163.90M 168.10M
Total current assets 355.40M 393.40M 487.00M 499.80M 418.60M
Long term investments - - - - -
Net tangible assets - - - 220.80M 321.10M
Short term investments - - - - -
Net receivables 103.80M 132.80M 142.80M 167.90M 131.20M
Long term debt 90.30M 125.30M 159.40M 226.30M 130.00M
Inventory 148.00M 138.80M 163.20M 190.30M 150.30M
Accounts payable 55.50M 54.30M 56.30M 67.90M 56.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -32.00000M -44.60000M -27.00000M -35.80000M -33.80000M
Additional paid in capital - - - - -
Common stock total equity - - - 0.50M 0.50M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -253.10000M -310.30000M
Treasury stock - - - - -21.30000M
Accumulated amortization - - - - -
Non currrent assets other 31.50M 23.20M 19.30M 17.60M 16.50M
Deferred long term asset charges - - - - -
Non current assets total 718.30M 760.80M 1205.40M 1287.10M 1176.00M
Capital lease obligations 28.60M 35.50M 41.10M 47.50M 57.50M
Long term debt total - - - 226.30M 130.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -27.50000M -64.30000M -135.40000M -21.00000M
Change to liabilities - - - 28.30M 21.50M
Total cashflows from investing activities -60.60000M -27.50000M 21.60M -135.40000M -21.00000M
Net borrowings -34.40000M -33.60000M -64.70000M 100.50M -50.00000M
Total cash from financing activities -37.00000M -49.10000M -94.20000M 56.70M -55.30000M
Change to operating activities - - - -4.10000M 26.00M
Net income -72.90000M -392.10000M -61.80000M 50.50M 5.20M
Change in cash -17.90000M 20.00M -40.00000M 9.20M 7.00M
Begin period cash flow 107.70M 87.70M 127.70M 118.50M 111.50M
End period cash flow 89.80M 107.70M 87.70M 127.70M 118.50M
Total cash from operating activities 74.70M 100.70M 32.40M 90.90M 87.30M
Issuance of capital stock - - - - -
Depreciation 38.90M 45.50M 46.10M 47.70M 38.30M
Other cashflows from investing activities -1.00000M -9.70000M - -116.10000M -
Dividends paid - - - - -
Change to inventory 0.20M 39.00M 4.70M -30.90000M 17.20M
Change to account receivables 30.90M -6.60000M 39.00M -24.70000M -10.80000M
Sale purchase of stock -3.30000M -12.80000M -19.10000M -45.50000M -11.50000M
Other cashflows from financing activities -37.00000M -2.70000M -10.40000M 398.80M 26.20M
Change to netincome - - - 17.00M 21.20M
Capital expenditures 31.60M 17.80M 17.80M 19.30M 21.00M
Change receivables - - - -24.70000M -10.80000M
Cash flows other operating - - - 3.00M -5.30000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 12.20M 11.00M
Change in working capital 9.80M 35.00M -18.00000M -24.30000M 26.00M
Stock based compensation 12.60M 13.80M 15.80M 15.90M 13.20M
Other non cash items 98.90M 398.50M 50.30M 1.10M 8.00M
Free cash flow 43.10M 82.90M 14.60M 71.60M 66.30M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVNS
Avanos Medical Inc		 0.03 0.12% 24.93 - 30.67 1.64 1.48 1.70 17.17
ABT
Abbott Laboratories		 2.70 3.07% 90.53 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 5.31 1.74% 310.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 1.36 1.72% 80.63 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.27 2.86% 45.60 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Avanos Medical Inc

5405 Windward Parkway, Alpharetta, GA, United States, 30004

Key Executives

Name Title Year Born
Mr. Joseph F. Woody CEO & Director 1966
Mr. Michael C. Greiner Sr. VP, CFO & Principal Accounting Officer 1973
Mr. David Edward Ball Sr. VP of Global Supply Chain & Procurement 1959
Mr. William David Haydon Sr. VP & GM of Pain Management 1967
Mr. Kerr W. Holbrook Sr. VP & GM of Chronic Care 1967
Mr. David Crawford VP of FP&A and Investor Relations and Treasurer NA
Ms. Michelle Scharfenberg Sr. VP and Chief Ethics & Compliance Officer NA
Ms. Mojirade James Sr. VP, Gen. Counsel & Corp. Sec. 1967
Mr. Scott Galovan VP of Strategy & Corp. Devel. NA
Mr. Arjun Ranjan Sarker Sr. VP of International 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.